In an eight-week monkey study, lean mass was 6% of weight lost with the antibody plus semaglutide versus 22% on semaglutide alone. iBio plans human trials in early 2027.
Recap by typeshit. Full story at BioPharm International.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Medical Xpress reports late stage results for Lilly's triple-action shot in patients with type 2 diabetes.
The post says four in ten patients drop GLP-1 drugs within a year over side effects, and pharma is turning to amylin-based shots as the next step.
Loading…